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INTRODUCTION
High-dose chemotherapy (HDCT) consisting of alky-
lating agents, etoposide, anthracyclines, and, more recently,
paclitaxel has been administered to a substantial number of
patients suffering from high-risk primary and stage IV
metastatic breast carcinoma [1-6].
We have reported on 104 responding metastatic breast
cancer patients who have received consolidating chemo-
therapy comprising either doxorubicin, cyclophosphamide,
and etoposide (CAVP) [7] or cisplatin, cyclophosphamide,
and etoposide (CCVP) [8]. Projected progression-free and
overall survival rates of 28.0% ± 4.7% and 58.6% ± 5.3%,
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ABSTRACT
We evaluated the feasibility of tandem-cycle high-dose chemotherapy (HDCT) with cisplatin, melphalan, and periph-
eral blood progenitor cells (PBPCs). Fifty patients with high-risk primary (n = 17) or stage IV breast cancer (n = 29)
or other malignancies (n = 4) received 2 cycles of intravenous melphalan, 20 to 151.8 mg/m2, and cisplatin, 200 mg/m2,
followed by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF. Starting at 40 mg/m2 of mel-
phalan, patients also received PBPCs. Delayed platelet recovery defined the maximum tolerated dose (MTD) for
melphalan at 101.2 mg/m2 per cycle. There were no treatment-related deaths. Cycle 2 was delivered at a median of
1.7 months after cycle 1; 72% of patients treated at the MTD received both cycles. Cycle 2 was omitted when
patients refused it or had disease progression or toxicities, primarily prolonged thrombocytopenia. Complete
response rates in stage IV breast cancer patients increased from 28% pre-HDCT to 55% after cycle 2. At a median
follow-up of 4.6 years (range, 1.5-8.1 years), 11 of 29 patients with stage IV breast carcinoma were alive with 5-year
projected progression-free and overall survival rates of 19% (95% confidence interval [CI], 7%-41%) and 39% (95%
CI, 20%-62%), respectively. Five-year projected progression-free and overall survival rates for patients with stage IV
breast cancer in complete response following HDCT versus all others were 35% (95% CI, 15%-70%) versus 0% (P =
.01) and 61% (95% CI, 35%-91%) versus 10% (95% CI, 2%-60%) (P = .003; log-rank test), respectively. Estrogen-
receptor positivity was predictive of reduced risk of progression (relative risk [RR], 0.25; 95% CI, 0.10-0.65; P = .003)
and death (RR, 0.27; 95% CI, 0.10-0.72; P = .009) after adjusting for response status. Five-year projected relapse-free
and overall survival rates were 71% (95% CI, 43%-96%) and 82% (95% CI, 56%-100%), respectively, for the
17 patients with high-risk primary breast cancer. Tandem-cycle high-dose melphalan and cisplatin with PBPCs is fea-
sible. Preliminary data suggest significant activity in selected patients with stage IV responding breast carcinoma.
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respectively, were observed at a median follow-up of
28 months [9]. The 3-year projected progression-free sur-
vival rate of 30% to 40% for patients in complete response
(CR) prior to HDCT in our series, as well as in others, sug-
gests that accomplishment of CR is necessary to improve
outcome [10]. We also reported encouraging 3.5-year pro-
jected progression-free survival rates for 114 high-risk
breast cancer patients with stage II (71%), stage IIIA (57%),
or stage IIIB inflammatory disease (50%) who received
either the CCVP or CAVP consolidation, which were in
line with reports by others [11,12].
In an attempt to further improve outcome by providing
both dose-intense and dose-dense therapy, we designed a
tandem regimen of cisplatin and melphalan, 2 alkylators
with demonstrated activity in breast cancer. Steep cytotoxic
dose-response curves are demonstrable in vitro for both
drugs [13-16]. We elected to give both cisplatin and mel-
phalan on a split schedule twice, 1 week apart during each
cycle, based on the acceptable toxicity profile we had
observed when high-dose cisplatin and etoposide were
administered on a similar schedule [8,17]. After assessing the
feasibility of delivering 2 cycles with growth factor support
only, we planned further dose escalation with peripheral
blood progenitor cells (PBPCs) to deﬁne the maximum tol-
erated dose (MTD).
PATIENTS AND METHODS
Patients
This study was approved by the Institutional Review
Board of the City of Hope National Medical Center. All
patients participating in the trial gave their written, volun-
tary, informed consent. Criteria for eligible breast cancer
patients were similar to those for single-cycle HDCT stud-
ies at our center: patients with high-risk primary breast can-
cer (stage II with ≥10 involved axillary nodes, stage IIIA, or
stage IIIB; a minimum of 3 cycles of prior neoadjuvant/
adjuvant therapy was required) or objectively responding
stage IV disease (with any type of chemo- or hormonal ther-
apy, radiation, or surgery). During the phase I portion of the
trial, patients with other malignancies not otherwise eligible
for higher priority protocols were also enrolled on this
study. A Karnofsky performance status of ≥80%, measured
creatinine clearance ≥75 mL/min, serum creatinine <1.4
mg/dL, serum bilirubin <1.5 mg/dL, aspartate aminotrans-
ferase and alanine aminotransferase ≤2 times normal levels,
forced expiratory volume in 1 minute (FEV1) ≥2 liters, diffu-
sion capacity >60% of predicted, and left ventricular ejec-
tion fraction (LVEF) of ≥55% were required. Bilateral bone
marrow biopsies, baseline audiogram, bone scan, and com-
puter-assisted tomography of previously involved or suspi-
cious sites of disease were performed on all patients. Breast
cancer patients with documented bone marrow metastasis
and any patient with central nervous system metastasis were
excluded.
Treatment Regimen
The treatment regimen and dose escalation scheme
(following a modified Fibonacci scale) for melphalan are
illustrated in Figure 1. After 6 hours of intravenous (IV)
hydration with normal saline, melphalan was administered
at a rate of 5 mg/min. Patients then received 25 g of IV
mannitol followed by cisplatin in 3% saline infused at a rate
of 25 mg/h. Saline hydration and appropriate electrolyte
supplementation continued at a rate of 200 mL/h for a min-
imum of 8 hours. Antiemetics and diuretics were used at the
discretion of the treating physician. Patients participating in
the phase I portion of this study received escalating total
doses of IV melphalan at 20 to 151.8 mg/m2 and ﬁxed doses
of 200 mg/m2 cisplatin per cycle; doses were divided
between days 1 and 8. No intrapatient escalation was
allowed. If unacceptable grade 3 and 4 hematopoietic toxici-
ties occurred at any given dose level, PBPCs were to be
administered to all subsequent patients. PBPCs were rein-
fused on day 13 (after a period inclusive of 5 terminal half-
lives of cisplatin) of both treatment cycles. Growth factors
(IV granulocyte-macrophage colony-stimulating factor
[GM-CSF], 250 µg/m2, in 3 patients and IV G-CSF, 5 µg/kg,
in all others) were administered from days 2 to 6 based on
data suggesting a benefit with concomitant growth factor
administration in adult leukemia patients [18,19] and from
day 9 until granulocyte recovery to >1000/µL for 3 consecu-
tive days. Patients were re-evaluated at 4 weeks after the
ﬁrst treatment cycle to determine eligibility for the second
course. Those with progressive disease following cycle 1 or
with organ functions not meeting the initial eligibility crite-
ria did not receive cycle 2. Delayed hematopoietic recovery
(<100,000 platelets/µL) beyond 7 weeks from day 1 of the
ﬁrst cycle and patient refusal were also reasons for withhold-
ing the second cycle. Both melphalan and cisplatin doses
were based on ideal body weight for all patients. Details of
supportive care have been reported earlier [11].
Stem Cell Mobilization and Collection
PBPC mobilization consisted of IV or subcutaneous
GM-CSF at 250 µg/m2 given for 6 days before and then
daily during stem cell collection in 3 patients. All other
patients received G-CSF at 5 µg/kg for 4 days before and
daily during stem cell leukapheresis until collection of
≥16 × 108 mononuclear cells (MNCs)/kg (median, 16.4 ×
108/kg; range, 7.9-18 × 108/kg) was achieved. A median of
9 leukaphereses (range, 4-17) per patient were performed.
PBPC apheresis and cryopreservation was performed as
previously reported [11].
Figure 1. Treatment schema of high-dose chemotherapy with tan-
dem-cycle melphalan and cisplatin, including dose escalation of mel-
phalan. G-CSF indicates granulocyte colony-stimulating factor; PBPC,
peripheral blood progenitor cells; IV, intravenous. 
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Toxicity Grading, Dose Adjustments, and Definition
of MTD
The dose of melphalan was escalated according to a
modiﬁed Fibonacci scheme (Figure 1); the cisplatin dose was
ﬁxed at 200 mg/m2 per cycle. Cisplatin and melphalan doses
were reduced by 25% for serum creatinine between 1.2 and
1.5 mg/dL, and both drugs were withheld if the serum crea-
tinine rose to >1.5 mg/dL. Grade 1 neurotoxicity mandated a
25% reduction of cisplatin dose; cisplatin was held for grade
2 or greater neurotoxicity. We used the NCI Division of
Cancer Treatment Common Toxicity Criteria (1991) for all
organ toxicities except for the hematologic and gastrointesti-
nal systems, where we followed our prior guidelines involving
autologous transplantation procedures. An absolute granulo-
cyte count (AGC) of ≤500/µL, a transfusion independent
platelet count of ≤10,000/µL lasting beyond 4 weeks of stem
cell reinfusion, and/or a platelet count of <100,000 by 7
weeks after day 1 of HDCT were considered grade 3 toxici-
ties [11]. Painful ulceration requiring narcotic analgesics
beyond 2 weeks was interpreted as grade 3 toxicity, and pain
with ulceration requiring ≤2 weeks of narcotics with the abil-
ity to drink represented grade 2 toxicity [11]. Once grade 3
toxicity was observed, 6 patients were to receive treatment at
that dose level; if no further grade 3 or greater toxicity was
observed, subsequent patients were entered at the next dose
level. If at any dose level 2 of 6 patients exhibited grade 3
toxicity or greater, or if a single patient experienced grade 4
toxicity, the dose-limiting toxicity was established. We
planned to treat 20 eligible breast cancer patients at the
MTD during the phase II portion of this study.
Follow-up and Evaluation of Response
Patients were re-evaluated with radiographs of all previ-
ously detectable abnormalities prior to administration of the
second cycle of HDCT and at least every 3 months there-
after. When evaluating response, CR was deﬁned as complete
disappearance of all clinical, radiographic, and laboratory
evidence of disease demonstrated on 2 evaluations at least
8 weeks apart. CR for disease confined to bone included
recalciﬁcation of all lesions and normalization of the bone
scan. Partial response (PR) was defined as at least a 50%
reduction in the sum of the products of the perpendicular
diameters of all measurable lesions found in 2 separate evalu-
ations at least 8 weeks apart. PR for disease conﬁned to bone
included decreased uptake and absence of new lesions on
bone scan with recalciﬁcation in at least half of all lesions.
Engraftment
Platelet independence was defined as the number of
days from PBPC reinfusion to the day after the last platelet
transfusion; accomplishment of absolute granulocyte count
(AGC) recovery required documentation of an AGC of
≥500/µL for 3 consecutive days.
Statistical Analysis
Median and range were computed to evaluate hemato-
poietic recovery and red blood cell and platelet transfusion
requirements. The Kaplan-Meier method was used to esti-
mate overall survival and progression-free survival rates
[20]. For patients with stage IV breast cancer, univariate
and multivariate Cox regression analyses examined the
number (0-1 versus >1) and sites of metastatic involvement
(liver versus other) before HDCT; CR versus all other cate-
gories before and after HDCT; estrogen- and proges-
terone-receptor status; radiation treatment; the number of
prior chemotherapy regimens for metastatic disease (0-1
versus >1); and prior exposure to a taxane. Both progres-
sion-free and overall survival rates were calculated from day
1 of the ﬁrst cycle of HDCT for all patients (including inel-
igible patients) with breast cancer.
RESULTS
Patient Characteristics
Between August 1991 and August 1998, 50 patients
were accrued. Pretreatment characteristics of the 46 patients
with breast cancer are listed in Table 1. The median age was
44 years (range, 25-61 years). Twenty-nine patients with
stage IV breast cancer were treated. Two patients with stage
IV breast cancer underwent stem cell aphereses and pro-
gressed prior to initiation of HDCT (sites of disease: chest
wall and axillary node); both patients became ineligible but
were treated in the study due to the treating physician’s
preference. A third breast cancer patient with stable disease
in her lung was also treated (as best “response”). All patients
were analyzed for toxicity, and all patients with breast cancer
(including those considered ineligible) were assessed for
response and survival. Nine of 29 patients received hor-
monal therapy for metastatic disease prior to enrollment in
this study; 10 patients received a taxane as part of induction
therapy for metastatic breast cancer; 8 patients received
prior radiation treatment to sites of metastatic involvement.
Table 1. Characteristics of Patients With Breast Cancer*
Age, y† 44 (25-61)
Stage IV patients (n = 29)
Time from diagnosis to first distant metastasis, mo 24 (0-121)
Time from first metastasis to HDCT, mo 7 (3-43)
Time from diagnosis to HDCT, mo 41 (6-128)
No. of adjuvant regimens before HDCT 1 (0-2)
No. of chemotherapy regimens before HDCT 2 (1-3)
Estrogen- or progesterone-receptor–positive tumor 19 (66)
Received adjuvant chemotherapy 17 (59)
Prior therapy with doxorubicin 27 (93)
Chemotherapy “induction” for metastatic disease 25 (86)
Prior radiation therapy to metastatic site 8 (28)
Received taxane 10 (35)
Surgical excision of metastatic site 9 (31)
Prior hormonal therapy 9 (31)
Stage II/III patients (n = 17)
Time from diagnosis to HDCT, mo 7 (5-23)
No. of chemotherapy regimens prior to HDCT 1 (1-2)
Received doxorubicin-containing 15 (88)
adjuvant/neoadjuvant therapy
Received taxane 2 (12)
Treated with modified radical mastectomy 13 (76)
Estrogen- or progesterone-receptor–positive tumor 10 (59)
Received post-HDCT tamoxifen 6 (35)
Received pre- or post-HDCT radiation therapy 14 (82)
*Data are median (range) or n (%). HDCT indicates high-dose
chemotherapy.
†All breast cancer patients.
Melphalan and Cisplatin With PBPC in Breast Cancer
287B B & M T
Of the 17 patients with high-risk primary breast cancer
treated, the majority of patients received a doxorubicin-
containing adjuvant regimen for at least 3 cycles; 2 patients
received a taxane. Fourteen patients received locoregional
radiation therapy (2 did not receive radiation due to physi-
cian’s choice; 1 patient refused). Six patients received tamox-
ifen following HDCT. Four patients, 1 with synovial sarcoma,
1 with peripheral neuroectodermal tumor (PNET), 1 with
adenosquamous carcinoma of the cervix, and 1 with multiple
myeloma, were also treated.
Six patients received HDCT without PBPC support at
dose level 1 (melphalan, 20 mg/m2 per cycle, and cisplatin,
200 mg/m2 per cycle). Three of these patients experienced
grade 3 neutropenias, and 4 patients experienced grade 4
thrombocytopenias, as classiﬁed by NCI Cancer Treatment
Common Toxicity Criteria, 1991 (grade 2 by modiﬁed NCI
Cancer Treatment Common Toxicity Criteria for patients
treated with autologous transplants [11]). All subsequent
patients received PBPCs after HDCT. We observed grade 4
thrombocytopenias at the highest dose level (level 6, mel-
phalan at 151.8 mg/m2 per cycle), and an intermediate dose
level 5 of melphalan, 125 mg/m2 per cycle, was then added.
Hence, during the phase I portion of the trial, patients were
treated at dose levels 1 (n = 6), 2 (n = 4), 3 (n = 4), 4 (n = 7),
5 (n = 5), and 6 (n = 3) of melphalan, as depicted in Figure 1.
Once the dose-limiting toxicity was reached, a total of
29 patients received HDCT at level 4 (MTD). Patients
received the second cycle of HDCT at a median of 51 days
(range, 34-75 days) from the ﬁrst day of the ﬁrst cycle.
Toxicities
Sixty-six percent of all patients and 72% of patients
treated at level 4 (MTD) received both treatment cycles.
Three patients progressed between cycles 1 and 2 (stage IV
breast cancer, 2 patients; Ewings’ sarcoma, 1 patient);
3 patients refused further treatment; and 1 patient’s platelet
count did not reach 100,000/µL by week 10, as required
per protocol. There were no treatment-related deaths. We
observed no grade 3 or 4 cardiac, renal, neurologic, liver, or
gastrointestinal toxicities; grade 2 nausea and vomiting,
stomatitis, and mucositis were seen in approximately 50% of
patients, regardless of dose level. One patient treated at dose
level 1 suffered an asymptomatic decrease in LVEF to 41%
following the ﬁrst cycle and received no further treatment.
A second patient treated at dose level 4 experienced a grade
2 transient decrease in LVEF from 59% to 20% during the
course of a septic episode while being treated with cycle 2;
LVEF then recovered to baseline. Two patients treated at
levels 1 and 4 experienced grade 1 supraventricular tachy-
cardia, which responded to medical management.
Severe respiratory insufﬁciency in the setting of polymi-
crobial (Nocardia, Candida tropicalis, and Streptococcus viridans
bacteremia) sepsis and documented alveolar hemorrhage
following cycle 2 was observed in 1 patient treated at level 4
(MTD). After extensive antibiotic treatment and ventilatory
and transfusion support, this patient was discharged from
the hospital with a subsequent full recovery.
Neurologic toxicities were mild: 1 patient treated at
dose level 6 required a hearing aid; 3 patients treated at level
4 experienced grade 1 tinnitus and/or high-frequency hear-
ing loss. One patient treated at dose level 1, one at dose
level 4, one at dose level 6, and 2 at dose level 5 developed
grade 1 paresthesiae.
The median peak serum creatinine level for all treatment
cycles was 1.1 mg/dL (range, 0.7-2.2 mg/dL). Two patients
(1 each at levels 3 and 4) required a 25% dose reduction of
both drugs on day 8 of the second cycle because of a rise in
serum creatinine to 1.3 mg/dL and 1.4 mg/dL, respectively.
Only 1 patient experienced grade 2 toxicity and did not
receive the second cycle of HDCT because of a drop in crea-
tinine clearance to 57 mL/min; her renal function normal-
ized by day 70. No patient required intravenous replacement
of electrolytes after recovery from HDCT.
During a total of 83 HDCT cycles, Gram-positive
(18 patients) and Gram-negative (13 patients) bacteremias
were seen frequently; 1 patient developed S. viridans bac-
teremia leading to endocarditis, with subsequent full recov-
ery. In addition, 6 episodes of C. difficile toxin-associated
enteritis and 6 cases of Herpes simplex culture positive perio-
ral or perigenital ulcers were documented. Three patients
received treatments for fungemia: 1 for C. albicans, 1 for C.
tropicalis, and 1 for C. parapsilosis. We observed 1 case of
Nocardia documented in a spleen biopsy; antibiotic treat-
ment slowly led to resolution of this infection. Three
patients underwent bronchoalveolar lavage as part of their
work-up for pulmonary infiltrates; cytomegalovirus
(1 patient) and C. albicans (2 patients) were seen on cytologi-
cal evaluation and responded to speciﬁc therapy.
Hematopoietic Toxicities/Engraftment
Six patients received treatment at level 1 (20 mg/m2
melphalan and 200 mg/m2 cisplatin). After the ﬁrst cycle of
therapy, AGC of 500/µL and platelet counts of 20,000/µL
were observed for a mean of 4 days (range, 0-14 days) and a
mean of 3.5 days (range, 0-14 days), respectively; only 3 of
6 patients received cycle 2 and experienced a mean of 1 day
(range, 0-10 days) and 0 (0) days of an AGC of 500/µL and
platelet counts of 20,000/µL. Hence, all subsequently
treated patients received PBPC rescue with a median of
9.25 × 108 MNCs/kg (range, 5.1-11.9 × 108 MNCs/kg) and
7.9 × 108 MNCs/kg (range, 5.9-13.9 × 108 MNC/kg) after
cycles 1 and 2, respectively. Hematopoietic toxicities for
patients receiving PBPCs and treated during the phase I
portion of the study are shown in Table 2.
Dose-limiting toxicity was prolonged thrombocytopenia:
at dose level 6 (melphalan, 151.8 mg/m2 per cycle), 1 patient
required 53 days to become platelet independent and
another patient suffered grade 4 thrombocytopenia (<20,000
platelets/µL through day 108) after the second course,
although a third patient recovered from both cycles without
delay. These 3 patients underwent a median of 10 aphereses
(range, 7-12) with median total yields of 16.7 × 108
MNCs/kg and 1.8 × 106 CD34+ cells/kg (range, 1.51-3.43 ×
106 CD34+ cells/kg). At the intermediate dose level 5 (mel-
phalan, 125 mg/m2 per cycle), only 1 patient received both
cycles (MNC yield, 16.55 × 108/kg; CD34+ cell yield, 5.5 ×
106 cells/kg). One patient required platelet transfusions
through day 36 of the ﬁrst cycle and did not reach a platelet
count of 50,000/µL until day 98 (MNC yield, 17.28 ×
108/kg; CD34+ cell yield, 0.59 × 106 cells/kg). Two patients
refused the second cycle, and 1 patient developed bacterial
endocarditis in the setting of pancytopenia; their PBPC
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product contained a median MNC count of 16.6 × 108/kg
(range, 16.25-17 × 108 cells/kg) and a median CD34+ cell
count of 4.78 × 106 cells/kg (range, 3.3-16 × 106 cells/kg).
Hence, level 4 (melphalan, 101.2 mg/m2 per cycle) became
the phase II dose (MTD). In all, 29 patients received treat-
ment at this dose level. The median (range) numbers of days
to reach an AGC of >500/µL and platelet transfusion inde-
pendence were 10 (5-21) and 10 (6-26) after cycle 1 and
10 (8-34) and 12 (7-114) after cycle 2, respectively. Data on
CD34+ cell yield was available from 24 patients treated at
MTD: the median CD34+ cell yield was 6.9 × 106 cells/kg
(range, 0.9-18.6 × 106 cells/kg). One patient did not receive
her second cycle due to lack of platelet recovery to
100,000/µL by week 10. One patient treated at MTD expe-
rienced the longest duration of both absolute granulocy-
topenia and platelet transfusion dependence after the second
cycle, because she inadvertently received all PBPC products
(all 3.5 × 106 CD34+ cells/kg) after cycle 1. Her granulocyte
count after cycle 2 remained at ≤500/µL for 34 days; she
required platelet transfusions for a period of 114 days; and
her platelet count remained under 50,000/µL beyond 1 year.
Response and Survival
Characteristics of all 29 patients with stage IV breast
cancer (20 of whom received treatment at the MTD) are
listed in Table 1. Of these patients, 8 (28%) were in CR and
18 in PR before HDCT (3 were ineligible). Two of the 18 eli-
gible patients in PR before HDCT achieved a CR after
cycle 1, and 4 others reached CR after cycle 2. Of the 3 inel-
igible patients, 1 patient had a progressive chest-wall lesion
first observed on the day of admission for cycle 1 and
achieved a CR following the ﬁrst cycle; the second patient
had a progressive axillary node metastasis and achieved PR
following the first cycle and CR after the second cycle.
Hence, the CR rate increased from 28% to 38% in the
29 patients with stage IV disease after the ﬁrst cycle and to
55% after the second cycle of HDCT. Two of 7 patients
with liver metastasis in partial remission achieved a CR and
are still in CR (1 at 25 months post-HDCT and 1 at
63 months post-HDCT), whereas a third patient, who was
in CR pre-HDCT, relapsed at 44 months post-HDCT and
is alive with disease at 55 months post-HDCT. Of the
4 patients in continuous partial remission with liver metasta-
sis post-HDCT, 3 patients died of progressive disease at 7,
16, and 37 months, respectively, and 1 patient is alive with
disease at 31 months post-HDCT. Overall, 3 of the 8 patients
transitioning into CR (2 with liver and 1 with peritoneum/
lung metastasis) are without recurrence at 25, 63, and
68 months post-HDCT, respectively. Prior therapies, pre-
HDCT status, and response to HDCT of the 29 patients
treated for stage IV breast cancer are listed in Table 3. Seven
patients (6 of whom were already in CR) received radiation
therapy post-HDCT to areas of previously involved sites
and went on to receive tamoxifen.
In a univariate Cox regression analysis of patients with
stage IV breast cancer, estrogen-receptor positivity (ERP)
and progesterone-receptor positivity (PRP) were associated
with lower risk for progression (RR for ERP, 0.32; 95% CI,
0.14-0.77; P = .01 and RR for PRP, 0.48; 95% CI, 0.21-1.11;
P = .09) and death from disease (RR for ERP, 0.25; 95% CI,
0.09-0.65; P = .005 and RR for PRP, 0.40; 95% CI, 0.15-
1.08; P = .07). There was no statistical effect of prior
chemotherapeutic regimens, sites of metastases (liver versus
other), prior taxane exposure, or radiation treatment to sites
of metastasis on outcome.
At a median follow-up of 4.6 years (range, 1.5-8.1 years),
the 5-year projected progression-free survival rate is 19%
(95% CI, 7%-41%) and the overall survival rate is 39%
(95% CI, 20%- 62%); 11 of 29 patients with stage IV dis-
ease are alive (Figure 2).
The 5-year projected progression-free survival rate for
stage IV breast cancer patients in CR pre-HDCT is 38%
(95% CI, 13%-92%) versus 11% (95% CI, 2%-41%) for all
others (P = .08; log-rank test); 5-year overall survival rate
was also better for patients in CR pre-HDCT at 75% (95%
CI, 44%-100%) versus 23% (95% CI, 0.08%-54%) (P =.01;
log-rank test) for all other patients treated with stage IV dis-
ease. Five-year projected progression-free and overall sur-
vival rates for patients with stage IV breast cancer in CR
after HDCT versus all others are illustrated in Figures 3
and 4 (progression-free survival rate, 35% [95% CI, 15%-
70%] versus 0%, P =.01; overall survival rate, 61% [95% CI,
35%-91%] versus 10% [95% CI, 2%-60%], P = .003).
In multivariate stepwise analysis, response (CR versus all
others) post-HDCT and receptor status persisted as inde-
pendent predictors of both progression-free and overall
Table 2. Hematopoietic Recovery and Transfusions in Patients Supported With Peripheral Blood Progenitor Cells*
Melphalan, Dose No. of Days to Days to Platelet No. of No. of PRBC
mg/m2 per cycle Level Cycle Patients AGC >500/µL† Independence† Transfusions† Transfusions†
40 2 1 4 14.5 (8-6) 11.5 (7-24) 8 (7-9) 6.5 (3-9)
2 3 13 (13-13) 13 (10-27) 6 (6-11) 6 (5-14)
67.6 3 1 3 9 (4-12) 7 (6-13) 4 (1-9) 2 (2-36)
2 3 9 (5-10) 10 (7-10) 3 (3-6) 5 (3-8)
101.2 4 1 7 10 (8-13) 10 (5-16) 6 (3-10) 7 (4-10)
2 6 10 (10-34)‡ 11 (7-114)‡ 10.5 (3-21)‡ 12 (5-36)‡
125 5 1 5 10 (9-14) 12 (7-36) 5 (4-9) 7 (5-15)
2 1 17 11 5 5
151.8 6 1 3 11 (9-13) 12 (11-53) 12 (3-14) 7 (4-38)
2 2 10.5 (10-11) 60.5 (13-108) 7.5 (6-9) 20 (13-27)
∗Patients were treated on the phase I portion of the trial. AGC indicates absolute granulocyte count; PRBC, packed red blood cell.
†Values are expressed as median (range).
‡Patient received no PBPC with cycle 2.
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survival rates. Patients in CR following HDCT had a similar
beneﬁt in both disease progression (RR, 0.28; 95% CI, 0.11-
0.84; P = .02) and overall survival rate (RR, 0.24; 95% CI,
0.09-0.66; P = .005). Patients with estrogen-receptor positive
tumors had a lower risk of progression (RR, 0.25; 95% CI,
0.10-0.62; P =.003) and death from disease (RR, 0.27; 95%
CI, 0.10-0.72; P = .009), after adjusting for response status.
The 5-year projected relapse-free and overall survival
rates are 71% (95% CI, 43%-96%) and 82% (95% CI,
56%-100%) for the 17 patients treated for high-risk pri-
mary breast carcinoma (Figure 5). Six patients (1 with stage
II, 1 with stage IIIA, and 4 with stage IIIB disease) have
relapsed at 6, 10, 16, 17, 18, and 88 months, respectively.
Both patients treated for multiple myeloma and
PNET progressed following cycle 1; the patient with syn-
ovial sarcoma relapsed after 7.6 months; and the patient
with adenosquamous carcinoma of the cervix progressed
at 7.3 months.
DISCUSSION
Although HDCT leads to higher CR rates in patients
with stage IV breast cancer, those already in CR before
HDCT seem to benefit the most from such treatment
[4,9,10,21]. A recent prospective randomized trial suggested
a lack of survival beneﬁt for patients in PR before receiving
HDCT, when HDCT (cyclophosphamide, thiotepa, and
carboplatin [STAMP V]) was compared to treatment with a
median of 8 cycles of cyclophosphamide, methotrexate, and
5-fluorouracil. The number of patients in CR before ran-
domization and the number of those transitioning from PR
to CR were equally low in both arms of that study, disallow-
ing any meaningful subset analysis [22]. In an attempt to
improve CR rates and to prolong survival, several phase I-II
trials of tandem HDCT cycles had been conducted in
patients with responding breast cancer. CR rates increased
after 2 HDCT cycles of CCVP to 55% (treatment-related
mortality, 9%) [4] from 25% to 39% after the ﬁrst and to
42% after the second cycle of tandem-cycle cyclophos-
phamide, carboplatin, and etoposide treatment (treatment-
related mortality, 4%) [23], and from 14% to 18% after
cyclophosphamide and thiotepa treatment and to 40% after
melphalan treatment (mortality rate, 7%) [24]. However,
these conversion rates were not much different from those
seen with single-cycle HDCT. More recent sequential
HDCT studies reported lower treatment-related mortality
rates: zero mortality was reported both with a regimen of
melphalan and subsequent STAMP V, resulting in a CR rate
of 55% after HDCT and post-intensification therapy [25]
and a CR conversion rate from 8% to 20% after sequential
paclitaxel, melphalan, and STAMP V treatments [26]. On
the other hand, a CR conversion rate from 20% pre-HDCT
to 33% after the first and 55% with tandem cycles of
cyclophosphamide, mitoxantrone, and carboplatin followed
Table 3. Response Status Prior to and Following High-Dose Chemotherapy (HDCT) in 29 Patients With Stage IV Breast Cancer*
Site of Metastasis Induction Treatment Response to Induction Response to Cycle 1 Response to Cycle 2
Liver Chemo Rx PR PD NA
Bone Chemo Rx, RT PR PR PR
Lymph node Surgery, RT CR CR NA
Liver/bone Chemo Rx, RT PR/SD PR/SD PR/SD
Liver/bone Chemo Rx CR/PR CR/PR CR/PR
Chest wall RT CR CR CR
Lymph node Chemo Rx PD PR CR†
Chest wall Chemo Rx, RT PD CR CR†
Bone Chemo Rx PR PR PR†
Chest wall Surgery CR CR CR
Bone Chemo Rx PR PR NA
Chest wall Surgery, RT CR CR CR
Bone Chemo Rx, RT PR PR PR
Lung/bone Chemo Rx, RT PR/PR PR/PR PR/PR
Lung/bone/peritoneum Chemo Rx PR/PR/PR PR/PR/PR CR
Chest wall Chemo Rx, surgery CR CR NA†
Liver/lung/bone Chemo Rx CR/PR/PR CR/PR/PR CR
Skin, lymph node Chemo Rx, surgery CR CR CR†
Chest wall, skin Chemo Rx, surgery CR CR CR†
Lung Chemo Rx PR CR CR
Liver Chemo Rx CR CR CR
Lung, bone Chemo Rx PR PR PR
Skin Chemo Rx PR PR PD
Bone Chemo Rx PR PR CR†
Lung Chemo Rx PR CR CR
Lung, bone Chemo Rx SD SD SD
Lymph node Chemo Rx PR PD PD
Liver Chemo Rx PR PR PR
Liver, lung, bone Chemo Rx PR PR CR
*Chemo Rx indicates chemotherapy; PR, partial response; PD, progressive disease; NA, not administered; RT, radiation therapy; CR, complete
response; SD, stable disease. 
†Patients received RT post-HDCT.
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by etoposide, thiotepa, and carboplatin was reported, but
only 45% of patients received both cycles and treatment-
related mortality was 3% [27]. The feasibility of a triple reg-
imen consisting of 2 cycles of epirubicin, ifosfamide, and
carboplatin and 1 cycle of paclitaxel, etoposide, and thiotepa
was tested in 21 patients: CR rate increased from 14% to
29% after completion of the third cycle [28]. Because it is
not possible to discern whether a CR is caused by the late
effects of the preceding HDCT cycle or by the cumulative
effect of repeated cycles, one must be cautious in interpret-
ing the above data. Limited information is available on the
role of tandem-cycle HDCT in patients with high-risk
breast cancer: in one such study, tandem-cycle HDCT with
ifosfamide, epirubicin, and carboplatin seemed feasible; the
preliminary outcome was comparable to those expected with
single-cycle HDCT [29]. In patients with inflammatory
breast cancer, high-dose sequential therapy with cyclophos-
phamide, doxorubicin ± 5-ﬂuorouracil, and PBPCs resulted
in a higher-than-expected 32% pathological CR rate [30].
To increase the CR rate and to minimize treatment-
related morbidity/mortality, we set out to develop a novel
double-alkylator regimen. We aimed at delivering both
cycles in the shortest possible interval based on the rationale
of the Skipper-Schabel model [31]. Tandem HDCT at the
MTD of melphalan, 101.2 mg/m2 per cycle, and cisplatin,
200 mg/m2 per cycle, resulted in acceptable toxicities. To
avoid reinfusion of potentially tumor-contaminated PBPCs,
we did not use PBPC rescue at the lowest dose level of mel-
phalan, although the effect of such occult contamination is
unclear [32,33]. Hematopoietic toxicities prompted us to
incorporate PBPCs at all subsequent dose levels. The need
for PBPCs was not surprising, because single-cycle/single-
agent melphalan, 100 mg/m2, followed by GM-CSF was
associated with prolonged granulocytopenia and thrombo-
cytopenia (medians of 31 and 63 days, respectively) in heav-
ily pretreated myeloma patients [34]. We have clearly
demonstrated, due to inadvertent reinfusion of all PBPC
products during the ﬁrst cycle to a patient treated with mel-
phalan, 101.2 mg/m2 per cycle, and cisplatin, 200 mg/m2 per
cycle, that PBPCs are mandatory with this regimen (34 days
of absolute granulocytopenia and 114 days of platelet trans-
fusion dependence was observed following cycle 2 due to
the lack of PBPCs).
At the time of study initiation (in 1991), we did not aim
to collect a target number of CD34+ cells in the apheresis
product. In our more recent series of clinically similar
patients who underwent mobilization following an identical
G-CSF dose and schedule, CD34+ cell yield correlated to
some degree with total nuclear cell count and/or MNC
count of the apheresis product. A median nucleated cell
count of 9.5 × 108/kg (range, 7.6-14.3 × 108/kg) was associ-
ated with a sufficient CD34+ cell yield of 3.1 × 106/kg
(range, 0.8-15.7 × 106/kg) [35]. Sixty-six percent of patients
in this study (72% of those treated at MTD [level 4, mel-
phalan 101.2 mg/m2 per cycle]) received both HDCT cycles
within a median interval of 1.7 months, suggesting that the
quality of apheresis products based solely on targeting a
MNC yield of 8 × 108/kg was sufficient; indeed, when
reviewed retrospectively, the median yield of CD34+ cells
Figure 2. Progression-free and overall survival of stage IV breast can-
cer patients treated with tandem-cycle high-dose chemotherapy con-
sisting of melphalan and cisplatin.
Figure 3. Progression-free survival of stage IV breast cancer patients
by response status (complete response [CR] versus all others) after
treatment with tandem-cycle high-dose chemotherapy.
Figure 4. Overall survival of stage IV breast cancer patients by
response status (compete response [CR] versus all others) after treat-
ment with tandem-cycle high-dose chemotherapy.
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was 6.9 × 106 cells/kg (range, 0.9-18.6 × 106 cells/kg) from
patients treated at MTD. However, 3 of the 8 patients (all
with heavily pretreated stage IV disease) accrued at the
2 highest dose levels suffered prolonged thrombocytopenias,
probably due to low CD34+ cell yields (in spite of the large
median number of 12 aphereses performed) with medians of
4.04 × 106 CD34+ cells/kg (range, 0.59-16 × 106 cells/kg)
and 1.8 × 106 CD34+ cells/kg (range, 1.51-3.43 × 106
cells/kg) at dose levels 5 and 6, respectively (data not
shown). Considering that 1 of these patients experienced
delayed platelet recovery after the second cycle, there exists
the possibility of stromal damage/cumulative damage to the
megakaryocytic lineage inflicted by the combination of
high-dose alkylator therapy. On the other hand, in a less
heavily pretreated patient population, it may be feasible to
collect sufficient numbers of CD34+ cells, leading to the
establishment of a higher MTD. Based on prior observa-
tions that 3-5 × 106/kg CD34+ cells per cycle is desirable for
optimal platelet recovery, we have incorporated such a tar-
get in our current HDCT trials [36,37]. Novel priming
agents such as recombinant human thrombopoietin [38],
higher doses of G-CSF, or combinations of chemotherapy
and growth factors may yield better-quality stem cell prod-
ucts [39]. Concomitant use of G-CSF and induction therapy
seems to have been justiﬁed in acute lymphocytic leukemia
leading to accelerated postinduction therapy recovery; to
prove a similar beneﬁt in our setting would require a ran-
domized trial [40]. Split reinfusion of PBPCs (reinfusion of
approximately 25% of PBPCs 2 days earlier and 75% of
PBPCs on day 13, 2 days, rather than all products given on
day 13) may also shorten the duration of neutropenia [35].
After tandem-cycle melphalan/cisplatin treatment, the
CR rate increased from 28% to 55%. Sixty-six percent of all
patients and 72% of patients treated at MTD received both
treatment cycles within short intervals (median, 1.7 months).
The conversion rate to CR and the feasibility of delivering
both cycles safely and in a timely manner compares favorably
to other tandem regimens.
Progression-free and overall survival rates were favor-
ably affected by achievement of CR (28% of patients) before
HDCT. However, contrary to earlier reports [10], a subset
of our patients (27%) who achieved CR only after HDCT
seems to have beneﬁted from such treatment as well, as doc-
umented by improved median progression-free and overall
survival rates for the entire subset of 55% of patients in CR
post-HDCT. Because the majority of patients reportedly
treated with tandem HDCT by other investigators had been
exposed to 1 induction regimen versus a median of 2 regi-
mens (range, 1-3) in our series, both the CR rate and the
35% 5-year projected relapse-free survival rate of patients in
CR at a relatively mature 4.6-year median follow-up for this
admittedly selected patient population are quite encourag-
ing [4,23-27]. Whether this outcome is truly due to the
cumulative effect of repeated cycles is unclear.
Our previous observation in 104 stage IV patients
treated with single-cycle HDCT and PBPC rescue [9], in
accordance with others [41,42], suggested that the presence
of persistent liver metastasis before HDCT is associated
with poor outcome. Pre-existence, or persistence, of liver
metastasis pre-HDCT lost its negative predictive value in
the current study, although the sample size of such patients
was small (7 of 29 stage IV patients).
In conclusion, tandem cycles of melphalan, 101.2 mg/m2,
and cisplatin, 200 mg/m2, followed by G-CSF–primed
PBPC support are feasible and result in substantial activity
in a group of selected patients with stage IV breast cancer.
Patients with stage IV breast cancer in CR, whether this had
been accomplished pre-HDCT or occurred as the result of
HDCT, enjoyed improved progression-free and overall sur-
vival rates. Although the sample size is small, a subset of
patients with extensive metastatic disease before HDCT,
including those with liver involvement, seemed to have ben-
efited from therapy. Relapse-free survival in patients with
high-risk primary disease is also promising, although follow-
up is still short. Should the outcome of already completed
and still ongoing randomized studies of single-cycle HDCT
reveal a beneﬁt of dose intensiﬁcation in either the adjuvant
or metastatic setting, the concept of dose-dense, tandem
HDCT versus single-cycle HDCT could be tested in a
prospective randomized setting.
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